Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Published:2023-12 Issue:6 Volume:8 Page:102034
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Tomita Y.^ORCID,Motzer R.J.^ORCID,Choueiri T.K.^ORCID,Rini B.I.^ORCID,Miyake H.^ORCID,Oya M.^ORCID,Albiges L.^ORCID,Aizawa M.,Umeyama Y.^ORCID,Wang J.,di Pietro A.,Schmidinger M.

Funder

Merck

Merck KGaA

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

2. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Powles;Ann Oncol,2021

3. Prescribing information,2022

4. Prescribing information,2022

5. Summary of product characteristics,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma;JAMA Network Open;2024-07-25

2. Perioperative systemic treatments in renal cell carcinoma;Frontiers in Oncology;2024-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP